Tianning Gu

Tianning Gu

Auto-generated profile, based on publicly available information

Tianning Gu

Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2022 in WIREs Mechanisms of Disease
Verified
Journal Article
Open access
TGTianning Gu
Tianning Gu
KHKejia Hu
Kejia Hu
XSXiaohui Si
Xiaohui Si
li yangli yang
li yang
HHHe Huang
He Huang
Chimeric antigen receptor T‐cell (CAR‐T) treatment has revolutionized the landscape of cancer therapy with significant efficacy on hematologic malignancy, especially in relapsed and refractory B cell malignancies. However, unexpected serious toxicities such as cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) still hamper its broad application. Clinical trials using CAR‐T cells targeting specific antigens on tumor cell surface have provided valuable information about the characteristics of ICANS. With unclear mechanism of ICANS after CAR‐T treatment, unremitting efforts have been devoted to further exploration. Clinical findings from patients with ICANS strongly indicated existence of overactivated peripheral immune response followed by endothelial activation‐induced blood–brain barrier (BBB) dysfunction, which triggers subsequent central nervous system (CNS) inflammation and neurotoxicity. Several animal models have been built but failed to fully replicate the whole spectrum of ICANS in human. Hopefully, novel and powerful technologies like single‐cell analysis may help decipher the precise cellular response within CNS from a different perspective when ICANS happens. Moreover, multidisciplinary cooperation among the subjects of immunology, hematology, and neurology will facilitate better understanding about the complex immune interaction between the peripheral, protective barriers, and CNS in ICANS. This review elaborates recent findings about ICANS after CAR‐T treatment from bed to bench, and discusses the potential cellular and molecular mechanisms that may promote effective management in the future.This article is categorized under: Cancer > Biomedical Engineering Immune System Diseases > Molecular and Cellular Physiology Neurological Diseases > Molecular and Cellular Physiology

22 October 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
XWXiujian Wang
Xiujian Wang
XTXiao Tao
Xiao Tao
PCPengjie Chen
Pengjie Chen
PJPenglei Jiang
Penglei Jiang
WLWenxiao Li
Wenxiao Li
HHHe Huang
He Huang
Clinical evidence supports the notion that T cell exhaustion and terminal differentiation pose challenges to the persistence and effectiveness of chimeric antigen receptor-T (CAR-T) cells. MEK1/2 inhibitors (MEKIs), widely used in cancer treatment due to their ability to inhibit aberrant MAPK signaling, have shown potential synergistic effects when combined with immunotherapy. However, the impact and mechanisms of MEKIs on CAR-T cells remain uncertain and controversial. To address this, we conducted a comprehensive investigation to determine whether MEKIs enhance or impair the efficacy of CAR-T cells. Our findings revealed that MEKIs attenuated CAR-T cell exhaustion and terminal differentiation induced by tonic signaling and antigen stimulation, thereby improving CAR-T cell efficacy against hematological and solid tumors. Remarkably, these effects were independent of the specific scFvs and costimulatory domains utilized in CARs. Mechanistically, analysis of bulk and single-cell transcriptional profiles demonstrates that the effect of MEK inhibition was related to diminish anabolic metabolism and downregulation of c-Fos and JunB. Additionally, the overexpression of c-Fos or JunB in CAR-T cells counteracted the effects of MEK inhibition. Furthermore, our Cut-and-Tag assay revealed that MEK inhibition downregulated the JunB-driven gene profiles associated with exhaustion, differentiation, anergy, glycolysis, and apoptosis. In summary, our research unveil the critical role of the MAPK-c-Fos-JunB axis in driving CAR-T cell exhaustion and terminal differentiation. These mechanistic insights significantly broaden the potential application of MEKIs to enhance the effectiveness of CAR-T therapy.

10 June 2026 in Nature Cancer
Verified
Journal Article
Closed access
DKDelin Kong
Delin Kong
TYTingting Yang
Tingting Yang
MZMengyu Zhao
Mengyu Zhao
LYLin Yang
Lin Yang
RJRuirui Jing
Ruirui Jing
HHHe Huang
He Huang

15 November 2022 in Blood
Verified
Journal Article
Open access
TGTianning Gu
Tianning Gu
WHWenfa Huang
Wenfa Huang
LWLei Wang
Lei Wang
YLYuqi Li
Yuqi Li
LWLixin Wang
Lixin Wang
HHHe Huang
He Huang
Aims & Objectives: Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the landscape of cancer therapy, obtaining significant efficacy espec